Back to List View Graph View

Programmed cell death 1 (PD-1)

Programmed cell death 1 (PD-1), also known as CD279 and encoded by the PDCD1 gene, is a cell-surface immunoinhibitory receptor of the immunoglobulin superfamily.

Where the papers sit

81 papers from the last 6 months study Programmed cell death 1 (PD-1) directly · updated from PubMed 16 Nov 2026

  • Predicting Immunotherapy Response

    Immunotherapy research is shifting toward response prediction, resistance mechanisms and more selective immune activation. CD28 PET, tumor mechanics, metabolic state, BMI and dyslipidemia are explored as response markers alongside CD8-positive T-cell and plasma-cell biology. Combination approaches target regulatory T cells, BLVRB, SPP1, cytoskeletal remodeling and immunogenic cell death. New PD-1-dependent antibodies and animal-directed therapies broaden development, but predictive biomarkers remain unsettled.

    19 papers · 23.5%

  • Overcoming Immunotherapy Resistance

    Resistance to PD-1 blockade is being addressed by rebuilding immune niches, altering metabolism and improving antigen delivery. Stem-like CD8+ T-cell reservoirs, effector-clone expansion and distant lymph nodes recur as sources of durable immunity. Microbiota, engineered bacteria, oral nanovaccines and microbial metabolites are paired with checkpoint blockade, while MerTK inhibition and methylglyoxal control target suppressive myeloid cells. Combination platforms increasingly aim to convert immunologically cold tumors without sacrificing systemic protection.

    16 papers · 19.8%

  • PD-L1 Targeting in Cancer

    PD-L1 research is moving from antibody blockade toward small-molecule inhibitors, structural optimization and combination strategies. miRNA regulation, PRKX stabilization and XIAP-PKC signaling recur as mechanisms of immune escape or acquired resistance. Clinical work pairs PD-1 blockade with chemotherapy or TGFβ inhibition, while biomarker studies seek better patient selection. Evidence remains heterogeneous across cancers and includes exploratory viral, economic and pharmacologic analyses.

    13 papers · 16%

  • Checkpoint Therapy and Immune Toxicity

    Checkpoint therapy is being refined across head and neck, cervical and melanoma settings, while immune toxicity remains a major clinical constraint. Neoadjuvant chemoimmunotherapy and pembrolizumab-based chemoradiation are being linked to systemic and tumoral immune correlates. PD-1 resistance and exhaustion involve distinct immune-cell states, including SIRPγ-associated and mast-cell phenotypes. Myocarditis, myasthenia gravis and other immune-related adverse events continue to define treatment risk.

    12 papers · 14.8%

  • Combination Immunotherapy in Liver Cancer

    Hepatocellular carcinoma treatment is moving toward PD-1 blockade combined with locoregional therapy, kinase inhibition, radiotherapy or targeted agents. Lenvatinib, apatinib and TACE recur in efforts to improve response and progression-free survival, with treatment timing still unresolved. Resistance is linked to glycolysis, cysteine metabolism, CD8+ T-cell exhaustion and immune-evasive tumor states. STK40, PPM1D, cGAS-STING and dendritic-cell lactylation provide mechanistic routes for restoring antitumor immunity.

    10 papers · 12.3%

  • PD-1 Therapy in Lung Cancer

    Non-small-cell lung cancer treatment is moving beyond pembrolizumab monotherapy toward antibody-drug conjugate, bispecific and chemotherapy combinations. Sacituzumab tirumotecan and ivonescimab are being tested against established PD-1-based regimens, particularly in PD-L1-positive or squamous disease. OX40L, METTL14/Wnt9a/β-catenin and PD-L1-directed radiosensitizers offer routes to deepen immune and radiation responses. Hypoxic neutrophil niches and metabolic reprogramming remain barriers to neoadjuvant efficacy.

    6 papers · 7.4%

  • T-Cell Receptor Signaling

    PD-1 inhibition is being defined as a spatial problem in T-cell receptor signaling. Unphosphorylated tyrosines, LCK, GRB2 and signaling condensates recur as mechanisms that restrain TCR and CD28 activation. Receptor-tethered modulators and localized PD-1 CAR-T approaches seek more selective control of signaling. Microbiome-loaded DC vaccines extend this work toward stronger, cross-reactive antitumor immunity.

    5 papers · 6.2%

PARADIGM SHIFT

PD-1 biology extends beyond T-cell checkpoint regulation to disease-relevant remodeling and activation of non-T immune cells

The melanoma study of mast cells and the murine study of Klebsiella pneumoniae-induced liver abscess both place PD-1 in functional non-T immune-cell programs: melanoma exposure remodeled mast cells toward a PD-1-positive, chymase-negative phenotype associated with metastasis and poor survival, while infection upregulated PD-1 on Kupffer cells and PD-1 antibody treatment improved bacterial clearance 42912494Oct 42894963Oct. This overturns the assumption that PD-1 is relevant primarily as a T-cell inhibitory checkpoint and broadens the consequences of PD-1 targeting to mast-cell state and macrophage-mediated antibacterial defense.

NEW DIRECTION

PD-1 directly inhibits T-cell signaling condensate formation through unphosphorylated inhibitory-motif tyrosines

The mechanistic study of the PD-1 cytoplasmic domain in reconstituted T-cell signaling systems and T cells found that PD-1 directly blocks TCR-induced LAT condensate formation, but that phosphorylation of its inhibitory-motif tyrosines abolishes rather than mediates this inhibition; substituting tryptophan restored the inhibitory effect 42721241Sep. This assigns PD-1 a role as a direct, phosphorylation-independent regulator of biomolecular condensate assembly through hydrogen-bond-donating aromatic residues, replacing the phosphorylation-centered mechanism described as the current working model in the abstract.

Papers

The 81 papers from the last 6 months that study Programmed cell death 1 (PD-1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Predicting Immunotherapy Response (19)
  1. Anti-PD-1 Therapy Alleviates Klebsiella pneumoniae-Induced Liver Abscess by Effectively Activating Kupffer Cells. Journal of microbiology and biotechnology · 19 Oct 2026 PMID 42894963
  2. Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response. Science advances · 16 Oct 2026 PMID 42886782
  3. Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death. Journal for immunotherapy of cancer · 1 Oct 2026 PMID 42823086
  4. Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia. Cancer discovery · 15 Sept 2026 PMID 42742315
  5. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  6. Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721225
  7. Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
  8. Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox. Scientific reports · 8 Sept 2026 PMID 42711346
  9. LIM and SH3 protein 1 deficiency confers resistance to cytotoxic lymphocyte-mediated lysis and immunotherapy in gastric cancer by disrupting cytoskeleton dynamics. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686372
  10. Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors. Journal of medicinal chemistry · 1 Sept 2026 PMID 42677819
  11. Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. Annals of medicine · 25 Aug 2026 PMID 42638413
  12. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  13. When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction. Breast cancer research and treatment · 12 Aug 2026 PMID 42584510
  14. Development of therapeutic PD-1 monoclonal antibodies for treatment of canine tumor. Veterinary immunology and immunopathology · 11 Aug 2026 PMID 42580049
  15. JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy. mAbs · 2 Aug 2026 PMID 42543223
  16. Mechanical properties of cancer cells reveal differential responses to anti-PD-1 immunotherapy. Analytical methods : advancing methods and applications · 31 Jul 2026 PMID 42535479
  17. Tumor-infiltrating plasma cell targets as a source for immunotherapies. Cancer cell · 27 Jul 2026 PMID 42508409
  18. Response classification changes the apparent predictive value of Par-6 family cell polarity regulator gamma for programmed cell death protein 1 blockade. International immunopharmacology · 24 Jul 2026 PMID 42497661
  19. Costimulatory biomarker-specific CD28 PET for early prediction of the response to PD-1 blockade in lung cancer. Molecular therapy : the journal of the American Society of Gene Therapy · 28 May 2026 PMID 42204816
Overcoming Immunotherapy Resistance (16)
  1. Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy. Immunity · 1 Oct 2026 PMID 42822444
  2. Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer. Journal for immunotherapy of cancer · 29 Sept 2026 PMID 42810811
  3. Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731874
  4. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell reports. Medicine · 2 Sept 2026 PMID 42685702
  5. Mathematical and Mouse Models Identify Regulatory T-cell Influx as a Key Determinant of Acquired Resistance to PD-1 Immunotherapy. Cancer research · 20 Aug 2026 PMID 42621701
  6. Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer. Journal for immunotherapy of cancer · 13 Aug 2026 PMID 42595355
  7. Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America · 5 Aug 2026 PMID 42555643
  8. Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. Cell host & microbe · 24 Jul 2026 PMID 42497859
  9. Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models. Science translational medicine · 22 Jul 2026 PMID 42485436
  10. Noninvasive deciphering of the immunosuppressive tumor microenvironment and evaluation of MerTK inhibitor mediated reversal of ICB resistance via MerTK-targeted PET. Bioorganic chemistry · 30 Jun 2026 PMID 42379015
  11. 4-Arylindolines Bearing a Pyrido[3,2-d]pyrimidine Scaffold as Dual Inhibitors of the PD-1/PD-L1 Interaction and NAMPT for Targeting Tumor Immunoevasion and Metabolism. Journal of medicinal chemistry · 29 Jun 2026 PMID 42366729
  12. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  13. Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
  14. Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. Oncogene · 15 Jun 2026 PMID 42298180
  15. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis. Molecular therapy : the journal of the American Society of Gene Therapy · 4 Jun 2026 PMID 42237539
  16. Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer. International immunopharmacology · 20 May 2026 PMID 42161051
PD-L1 Targeting in Cancer (13)
  1. Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
  2. Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720488
  3. PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype. Journal for immunotherapy of cancer · 9 Sept 2026 PMID 42716706
  4. Conserved miRNA regulators of PD-1/PD-L1 in glioblastoma and colorectal cancer. RNA biology · 19 Aug 2026 PMID 42616478
  5. Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait. Clinical drug investigation · 13 Aug 2026 PMID 42587242
  6. Viral coinfections and checkpoint-marker expression in HIV: An exploratory HCV-Related CD4⁺ T-Cell PD-L1 pattern. Immunologic research · 11 Aug 2026 PMID 42579169
  7. Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. Journal of hematology & oncology · 21 Jul 2026 PMID 42477829
  8. Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity. Journal of medicinal chemistry · 3 Jul 2026 PMID 42394434
  9. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347868
  10. Small Molecule Activators of Antitumor Immunity. Accounts of chemical research · 24 Jun 2026 PMID 42342561
  11. Toward Nano-Nutritional Medicine: A Remotely Activated Trans-Vaccenic Acid-Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261893
  12. Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. Proceedings of the National Academy of Sciences of the United States of America · 3 Jun 2026 PMID 42234523
  13. Temperature Dependent Motions of N-Terminal Loop in PD-1 Determine the Affinity Towards Nivolumab. Journal of molecular recognition : JMR · 27 May 2026 PMID 42199044
Checkpoint Therapy and Immune Toxicity (12)
  1. Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival. Oncoimmunology · 23 Oct 2026 PMID 42912494
  2. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
  3. Proteomic and Metabolomic Analysis of Immune-Related Adverse Events in Patients Treated with PD-1 Inhibitors. Journal of proteome research · 4 Sept 2026 PMID 42695906
  4. Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
  5. Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Aug 2026 PMID 42594032
  6. Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. Cell reports. Medicine · 4 Aug 2026 PMID 42551432
  7. Investigation of PDCD1 Gene Polymorphisms and Haplotypes in COVID-19 Severity and Outcome in a Brazilian Population. Journal of medical virology · 30 Jul 2026 PMID 42530413
  8. omitting neck dissection in cT3-4N0M0 oral squamous cell carcinoma with Imaging-Negative nodes after neoadjuvant chemoimmunotherapy: A retrospective cohort study. Oral oncology · 8 Jul 2026 PMID 42419164
  9. Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
  10. Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347893
  11. Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line. Biochemical and biophysical research communications · 8 Jun 2026 PMID 42259198
  12. Signal regulatory protein γ is associated with an exhaustion-prone immune microenvironment in metastatic melanoma. Experimental cell research · 21 May 2026 PMID 42167713
Combination Immunotherapy in Liver Cancer (10)
  1. Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma. Medicine · 17 Oct 2026 PMID 42888556
  2. Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation. Signal transduction and targeted therapy · 27 Sept 2026 PMID 42802226
  3. Integrative multi-omics landscape and diagnostic-therapeutic modelling of steatohepatitic hepatocellular carcinoma. Gut · 22 Sept 2026 PMID 42772859
  4. Multi-omics and spatial transcriptomics reveal that S100A10 drives CD8+ T-cell exhaustion and immune evasion in hepatocellular carcinoma through cPLA2-5-LOX-mediated arachidonic acid metabolism and ferroptosis. International immunopharmacology · 13 Sept 2026 PMID 42732672
  5. Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy. Liver international : official journal of the International Association for the Study of the Liver · 28 Aug 2026 PMID 42661423
  6. Inhibiting PPM1D Perturbs Mitochondrial Integrity to Stimulate cGAS-STING Signaling and Antitumor Immunity. Cancer research · 30 Jun 2026 PMID 42378680
  7. Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
  8. WNK4 Enhances Anti-PD-1 Resistance and Promotes Tumor Progression in Hepatocellular Carcinoma by Reprogramming Cysteine Metabolism in Cancer-Associated Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42253146
  9. Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration. Cancer cell · 28 May 2026 PMID 42208540
  10. Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma. Molecular cancer therapeutics · 20 May 2026 PMID 42159460
PD-1 Therapy in Lung Cancer (6)
  1. Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731877
  2. HIF1A+CSF3R+ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC. Journal for immunotherapy of cancer · 8 Sept 2026 PMID 42711068
  3. Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. European journal of pharmacology · 6 Aug 2026 PMID 42562044
  4. Radiosensitization effect of PD-L1-targeted small molecules with direct antitumor activity on non-small cell lung Cancer. Bioorganic chemistry · 14 Jul 2026 PMID 42447749
  5. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet (London, England) · 31 May 2026 PMID 42218899
  6. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
T-Cell Receptor Signaling (5)
  1. CD28 costimulation is organized by signaling condensates and counteracted by PD-1. Proceedings of the National Academy of Sciences of the United States of America · 22 Oct 2026 PMID 42905561
  2. Unphosphorylated tyrosines mediate PD-1 inhibition of T cell signaling condensate formation. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721241
  3. DC vaccine loaded with Bacteroides fragilis elicits functional cross-reactivity and enhances anti-PD-1 immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy · 14 Aug 2026 PMID 42596550
  4. Localized PD-1 CAR T therapy reprograms neuroinflammation. Cell · 21 Jul 2026 PMID 42480527
  5. Receptor-Tethered Cytosolic Modulators Enable Spatial Control of Cell Signaling Specificity. ACS nano · 22 Jun 2026 PMID 42329051

By study type

Clinical trials (8)
  1. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
  2. Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Aug 2026 PMID 42594032
  3. Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. Cell reports. Medicine · 4 Aug 2026 PMID 42551432
  4. Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
  5. Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347893
  6. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347868
  7. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet (London, England) · 31 May 2026 PMID 42218899
  8. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
Observational studies and case reports (7)
  1. Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma. Medicine · 17 Oct 2026 PMID 42888556
  2. Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast cancer research and treatment · 9 Sept 2026 PMID 42714605
  3. Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy. Liver international : official journal of the International Association for the Study of the Liver · 28 Aug 2026 PMID 42661423
  4. Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. Annals of medicine · 25 Aug 2026 PMID 42638413
  5. When immunotherapy hurts: neoadjuvant PD-1 inhibitors increase opioid use after mastectomy with reconstruction. Breast cancer research and treatment · 12 Aug 2026 PMID 42584510
  6. omitting neck dissection in cT3-4N0M0 oral squamous cell carcinoma with Imaging-Negative nodes after neoadjuvant chemoimmunotherapy: A retrospective cohort study. Oral oncology · 8 Jul 2026 PMID 42419164
  7. Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
Human data, design not indexed (13)
  1. Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response. Science advances · 16 Oct 2026 PMID 42886782
  2. Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox. Scientific reports · 8 Sept 2026 PMID 42711346
  3. Proteomic and Metabolomic Analysis of Immune-Related Adverse Events in Patients Treated with PD-1 Inhibitors. Journal of proteome research · 4 Sept 2026 PMID 42695906
  4. Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
  5. Conserved miRNA regulators of PD-1/PD-L1 in glioblastoma and colorectal cancer. RNA biology · 19 Aug 2026 PMID 42616478
  6. Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait. Clinical drug investigation · 13 Aug 2026 PMID 42587242
  7. Viral coinfections and checkpoint-marker expression in HIV: An exploratory HCV-Related CD4⁺ T-Cell PD-L1 pattern. Immunologic research · 11 Aug 2026 PMID 42579169
  8. Investigation of PDCD1 Gene Polymorphisms and Haplotypes in COVID-19 Severity and Outcome in a Brazilian Population. Journal of medical virology · 30 Jul 2026 PMID 42530413
  9. Response classification changes the apparent predictive value of Par-6 family cell polarity regulator gamma for programmed cell death protein 1 blockade. International immunopharmacology · 24 Jul 2026 PMID 42497661
  10. Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. Journal of hematology & oncology · 21 Jul 2026 PMID 42477829
  11. Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer. Oncogene · 15 Jun 2026 PMID 42298180
  12. Temperature Dependent Motions of N-Terminal Loop in PD-1 Determine the Affinity Towards Nivolumab. Journal of molecular recognition : JMR · 27 May 2026 PMID 42199044
  13. Signal regulatory protein γ is associated with an exhaustion-prone immune microenvironment in metastatic melanoma. Experimental cell research · 21 May 2026 PMID 42167713
Preclinical: animal, cell and lab studies (48)
  1. Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival. Oncoimmunology · 23 Oct 2026 PMID 42912494
  2. CD28 costimulation is organized by signaling condensates and counteracted by PD-1. Proceedings of the National Academy of Sciences of the United States of America · 22 Oct 2026 PMID 42905561
  3. Anti-PD-1 Therapy Alleviates Klebsiella pneumoniae-Induced Liver Abscess by Effectively Activating Kupffer Cells. Journal of microbiology and biotechnology · 19 Oct 2026 PMID 42894963
  4. Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death. Journal for immunotherapy of cancer · 1 Oct 2026 PMID 42823086
  5. Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy. Immunity · 1 Oct 2026 PMID 42822444
  6. Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer. Journal for immunotherapy of cancer · 29 Sept 2026 PMID 42810811
  7. Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation. Signal transduction and targeted therapy · 27 Sept 2026 PMID 42802226
  8. Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
  9. Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731877
  10. Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731874
  11. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  12. Unphosphorylated tyrosines mediate PD-1 inhibition of T cell signaling condensate formation. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721241
  13. Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721225
  14. Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720488
  15. PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype. Journal for immunotherapy of cancer · 9 Sept 2026 PMID 42716706
  16. HIF1A+CSF3R+ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC. Journal for immunotherapy of cancer · 8 Sept 2026 PMID 42711068
  17. LIM and SH3 protein 1 deficiency confers resistance to cytotoxic lymphocyte-mediated lysis and immunotherapy in gastric cancer by disrupting cytoskeleton dynamics. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686372
  18. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell reports. Medicine · 2 Sept 2026 PMID 42685702
  19. Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors. Journal of medicinal chemistry · 1 Sept 2026 PMID 42677819
  20. Mathematical and Mouse Models Identify Regulatory T-cell Influx as a Key Determinant of Acquired Resistance to PD-1 Immunotherapy. Cancer research · 20 Aug 2026 PMID 42621701
  21. DC vaccine loaded with Bacteroides fragilis elicits functional cross-reactivity and enhances anti-PD-1 immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy · 14 Aug 2026 PMID 42596550
  22. Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer. Journal for immunotherapy of cancer · 13 Aug 2026 PMID 42595355
  23. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  24. Development of therapeutic PD-1 monoclonal antibodies for treatment of canine tumor. Veterinary immunology and immunopathology · 11 Aug 2026 PMID 42580049
  25. Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. European journal of pharmacology · 6 Aug 2026 PMID 42562044
  26. Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America · 5 Aug 2026 PMID 42555643
  27. JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy. mAbs · 2 Aug 2026 PMID 42543223
  28. Mechanical properties of cancer cells reveal differential responses to anti-PD-1 immunotherapy. Analytical methods : advancing methods and applications · 31 Jul 2026 PMID 42535479
  29. Tumor-infiltrating plasma cell targets as a source for immunotherapies. Cancer cell · 27 Jul 2026 PMID 42508409
  30. Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. Cell host & microbe · 24 Jul 2026 PMID 42497859
  31. Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models. Science translational medicine · 22 Jul 2026 PMID 42485436
  32. Localized PD-1 CAR T therapy reprograms neuroinflammation. Cell · 21 Jul 2026 PMID 42480527
  33. Radiosensitization effect of PD-L1-targeted small molecules with direct antitumor activity on non-small cell lung Cancer. Bioorganic chemistry · 14 Jul 2026 PMID 42447749
  34. Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity. Journal of medicinal chemistry · 3 Jul 2026 PMID 42394434
  35. Noninvasive deciphering of the immunosuppressive tumor microenvironment and evaluation of MerTK inhibitor mediated reversal of ICB resistance via MerTK-targeted PET. Bioorganic chemistry · 30 Jun 2026 PMID 42379015
  36. Inhibiting PPM1D Perturbs Mitochondrial Integrity to Stimulate cGAS-STING Signaling and Antitumor Immunity. Cancer research · 30 Jun 2026 PMID 42378680
  37. 4-Arylindolines Bearing a Pyrido[3,2-d]pyrimidine Scaffold as Dual Inhibitors of the PD-1/PD-L1 Interaction and NAMPT for Targeting Tumor Immunoevasion and Metabolism. Journal of medicinal chemistry · 29 Jun 2026 PMID 42366729
  38. Small Molecule Activators of Antitumor Immunity. Accounts of chemical research · 24 Jun 2026 PMID 42342561
  39. Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones. Cancer research · 22 Jun 2026 PMID 42329854
  40. Receptor-Tethered Cytosolic Modulators Enable Spatial Control of Cell Signaling Specificity. ACS nano · 22 Jun 2026 PMID 42329051
  41. Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
  42. Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line. Biochemical and biophysical research communications · 8 Jun 2026 PMID 42259198
  43. WNK4 Enhances Anti-PD-1 Resistance and Promotes Tumor Progression in Hepatocellular Carcinoma by Reprogramming Cysteine Metabolism in Cancer-Associated Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42253146
  44. Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. Proceedings of the National Academy of Sciences of the United States of America · 3 Jun 2026 PMID 42234523
  45. Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration. Cancer cell · 28 May 2026 PMID 42208540
  46. Costimulatory biomarker-specific CD28 PET for early prediction of the response to PD-1 blockade in lung cancer. Molecular therapy : the journal of the American Society of Gene Therapy · 28 May 2026 PMID 42204816
  47. Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer. International immunopharmacology · 20 May 2026 PMID 42161051
  48. Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma. Molecular cancer therapeutics · 20 May 2026 PMID 42159460
Unclassified: not yet indexed with MeSH (5)
  1. Integrative multi-omics landscape and diagnostic-therapeutic modelling of steatohepatitic hepatocellular carcinoma. Gut · 22 Sept 2026 PMID 42772859
  2. Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia. Cancer discovery · 15 Sept 2026 PMID 42742315
  3. Multi-omics and spatial transcriptomics reveal that S100A10 drives CD8+ T-cell exhaustion and immune evasion in hepatocellular carcinoma through cPLA2-5-LOX-mediated arachidonic acid metabolism and ferroptosis. International immunopharmacology · 13 Sept 2026 PMID 42732672
  4. Toward Nano-Nutritional Medicine: A Remotely Activated Trans-Vaccenic Acid-Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261893
  5. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis. Molecular therapy : the journal of the American Society of Gene Therapy · 4 Jun 2026 PMID 42237539